REPORT ID 5367

Global Urological Cancer Therapeutics Drugs Market Research Report 2017

Publish Date
21-Dec-17
Pages
117
Format
Electronic (PDF)

In this report, the global Urological Cancer Therapeutics Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Urological Cancer Therapeutics Drugs in these regions, from 2012 to 2022 (forecast), covering
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
Global Urological Cancer Therapeutics Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
    Novartis
    Pfizer
    Johnson & Johnson
    AstraZeneca
    Astellas
    Bristol-Myers Squibb
    Abbott Laboratories
    Celgene Corporation
    Dendreon Corporation
    Ferring Pharmaceuticals
    GlaxoSmithKline plc
    Indevus Pharmaceuticals Inc
    Ipsen
    Roche Healthcare
    Sanofi S.A.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Xofigo (radium Ra 223 dichloride)
    Jevtana (cabazitaxel)
    Inlyta (axitinib)
    Votrient (pazopanib hydrochloride)
    Sutent (sunitinib malate)
    Zytiga (abiraterone acetate)
    Xtandi (enzalutamide)
    Opdivo (nivolumab)
    Provenge (sipuleucel-T)
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
    Hospital
    Medical Research Laboratory
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Urological Cancer Therapeutics Drugs Market Research Report 2017
1 Urological Cancer Therapeutics Drugs Market Overview
    1.1 Product Overview and Scope of Urological Cancer Therapeutics Drugs
    1.2 Urological Cancer Therapeutics Drugs Segment by Type (Product Category)
        1.2.1 Global Urological Cancer Therapeutics Drugs Production and CAGR (%) Comparison by Type (Product Category)(2012-2022)
        1.2.2 Global Urological Cancer Therapeutics Drugs Production Market Share by Type (Product Category) in 2016
        1.2.3 Xofigo (radium Ra 223 dichloride)
        1.2.4 Jevtana (cabazitaxel)
        1.2.5 Inlyta (axitinib)
        1.2.6 Votrient (pazopanib hydrochloride)
        1.2.7 Sutent (sunitinib malate)
        1.2.8 Zytiga (abiraterone acetate)
        1.2.9 Xtandi (enzalutamide)
        1.2.10 Opdivo (nivolumab)
        1.2.11 Provenge (sipuleucel-T)
    1.3 Global Urological Cancer Therapeutics Drugs Segment by Application
        1.3.1 Urological Cancer Therapeutics Drugs Consumption (Sales) Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Medical Research Laboratory
        1.3.4 Others
    1.4 Global Urological Cancer Therapeutics Drugs Market by Region (2012-2022)
        1.4.1 Global Urological Cancer Therapeutics Drugs Market Size (Value) and CAGR (%) Comparison by Region (2012-2022)
        1.4.2 North America Status and Prospect (2012-2022)
        1.4.3 Europe Status and Prospect (2012-2022)
        1.4.4 China Status and Prospect (2012-2022)
        1.4.5 Japan Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Status and Prospect (2012-2022)
        1.4.7 India Status and Prospect (2012-2022)
    1.5 Global Market Size (Value) of Urological Cancer Therapeutics Drugs (2012-2022)
        1.5.1 Global Urological Cancer Therapeutics Drugs Revenue Status and Outlook (2012-2022)
        1.5.2 Global Urological Cancer Therapeutics Drugs Capacity, Production Status and Outlook (2012-2022)

2 Global Urological Cancer Therapeutics Drugs Market Competition by Manufacturers
    2.1 Global Urological Cancer Therapeutics Drugs Capacity, Production and Share by Manufacturers (2012-2017)
        2.1.1 Global Urological Cancer Therapeutics Drugs Capacity and Share by Manufacturers (2012-2017)
        2.1.2 Global Urological Cancer Therapeutics Drugs Production and Share by Manufacturers (2012-2017)
    2.2 Global Urological Cancer Therapeutics Drugs Revenue and Share by Manufacturers (2012-2017)
    2.3 Global Urological Cancer Therapeutics Drugs Average Price by Manufacturers (2012-2017)
    2.4 Manufacturers Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Sales Area and Product Type
    2.5 Urological Cancer Therapeutics Drugs Market Competitive Situation and Trends
        2.5.1 Urological Cancer Therapeutics Drugs Market Concentration Rate
        2.5.2 Urological Cancer Therapeutics Drugs Market Share of Top 3 and Top 5 Manufacturers
        2.5.3 Mergers & Acquisitions, Expansion

3 Global Urological Cancer Therapeutics Drugs Capacity, Production, Revenue (Value) by Region (2012-2017)
    3.1 Global Urological Cancer Therapeutics Drugs Capacity and Market Share by Region (2012-2017)
    3.2 Global Urological Cancer Therapeutics Drugs Production and Market Share by Region (2012-2017)
    3.3 Global Urological Cancer Therapeutics Drugs Revenue (Value) and Market Share by Region (2012-2017)
    3.4 Global Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.5 North America Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.6 Europe Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.7 China Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.8 Japan Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.9 Southeast Asia Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
    3.10 India Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Urological Cancer Therapeutics Drugs Supply (Production), Consumption, Export, Import by Region (2012-2017)
    4.1 Global Urological Cancer Therapeutics Drugs Consumption by Region (2012-2017)
    4.2 North America Urological Cancer Therapeutics Drugs Production, Consumption, Export, Import (2012-2017)
    4.3 Europe Urological Cancer Therapeutics Drugs Production, Consumption, Export, Import (2012-2017)
    4.4 China Urological Cancer Therapeutics Drugs Production, Consumption, Export, Import (2012-2017)
    4.5 Japan Urological Cancer Therapeutics Drugs Production, Consumption, Export, Import (2012-2017)
    4.6 Southeast Asia Urological Cancer Therapeutics Drugs Production, Consumption, Export, Import (2012-2017)
    4.7 India Urological Cancer Therapeutics Drugs Production, Consumption, Export, Import (2012-2017)

5 Global Urological Cancer Therapeutics Drugs Production, Revenue (Value), Price Trend by Type
    5.1 Global Urological Cancer Therapeutics Drugs Production and Market Share by Type (2012-2017)
    5.2 Global Urological Cancer Therapeutics Drugs Revenue and Market Share by Type (2012-2017)
    5.3 Global Urological Cancer Therapeutics Drugs Price by Type (2012-2017)
    5.4 Global Urological Cancer Therapeutics Drugs Production Growth by Type (2012-2017)

6 Global Urological Cancer Therapeutics Drugs Market Analysis by Application
    6.1 Global Urological Cancer Therapeutics Drugs Consumption and Market Share by Application (2012-2017)
    6.2 Global Urological Cancer Therapeutics Drugs Consumption Growth Rate by Application (2012-2017)
    6.3 Market Drivers and Opportunities
        6.3.1 Potential Applications
        6.3.2 Emerging Markets/Countries

7 Global Urological Cancer Therapeutics Drugs Manufacturers Profiles/Analysis
    7.1 Novartis
        7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.1.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.1.2.1 Product A
            7.1.2.2 Product B
        7.1.3 Novartis Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.1.4 Main Business/Business Overview
    7.2 Pfizer
        7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.2.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.2.2.1 Product A
            7.2.2.2 Product B
        7.2.3 Pfizer Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.2.4 Main Business/Business Overview
    7.3 Johnson & Johnson
        7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.3.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.3.2.1 Product A
            7.3.2.2 Product B
        7.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.3.4 Main Business/Business Overview
    7.4 AstraZeneca
        7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.4.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.4.2.1 Product A
            7.4.2.2 Product B
        7.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.4.4 Main Business/Business Overview
    7.5 Astellas
        7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.5.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.5.2.1 Product A
            7.5.2.2 Product B
        7.5.3 Astellas Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.5.4 Main Business/Business Overview
    7.6 Bristol-Myers Squibb
        7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.6.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.6.2.1 Product A
            7.6.2.2 Product B
        7.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.6.4 Main Business/Business Overview
    7.7 Abbott Laboratories
        7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.7.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.7.2.1 Product A
            7.7.2.2 Product B
        7.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.7.4 Main Business/Business Overview
    7.8 Celgene Corporation
        7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.8.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.8.2.1 Product A
            7.8.2.2 Product B
        7.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.8.4 Main Business/Business Overview
    7.9 Dendreon Corporation
        7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.9.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.9.2.1 Product A
            7.9.2.2 Product B
        7.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.9.4 Main Business/Business Overview
    7.10 Ferring Pharmaceuticals
        7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
        7.10.2 Urological Cancer Therapeutics Drugs Product Category, Application and Specification
            7.10.2.1 Product A
            7.10.2.2 Product B
        7.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Capacity, Production, Revenue, Price and Gross Margin (2012-2017)
        7.10.4 Main Business/Business Overview
    7.11 GlaxoSmithKline plc
    7.12 Indevus Pharmaceuticals Inc
    7.13 Ipsen
    7.14 Roche Healthcare
    7.15 Sanofi S.A.

8 Urological Cancer Therapeutics Drugs Manufacturing Cost Analysis
    8.1 Urological Cancer Therapeutics Drugs Key Raw Materials Analysis
       8.1.1 Key Raw Materials
       8.1.2 Price Trend of Key Raw Materials
       8.1.3 Key Suppliers of Raw Materials
       8.1.4 Market Concentration Rate of Raw Materials
    8.2 Proportion of Manufacturing Cost Structure
       8.2.1 Raw Materials
       8.2.2 Labor Cost
       8.2.3 Manufacturing Expenses
    8.3 Manufacturing Process Analysis of Urological Cancer Therapeutics Drugs

9 Industrial Chain, Sourcing Strategy and Downstream Buyers
    9.1 Urological Cancer Therapeutics Drugs Industrial Chain Analysis
    9.2 Upstream Raw Materials Sourcing
    9.3 Raw Materials Sources of Urological Cancer Therapeutics Drugs Major Manufacturers in 2015
    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders
    10.1 Marketing Channel
        10.1.1 Direct Marketing
        10.1.2 Indirect Marketing
        10.1.3 Marketing Channel Development Trend
    10.2 Market Positioning
        10.2.1 Pricing Strategy
        10.2.2 Brand Strategy
        10.2.3 Target Client
    10.3 Distributors/Traders List

11 Market Effect Factors Analysis
    11.1 Technology Progress/Risk
        11.1.1 Substitutes Threat
        11.1.2 Technology Progress in Related Industry
    11.2 Consumer Needs/Customer Preference Change
    11.3 Economic/Political Environmental Change

12 Global Urological Cancer Therapeutics Drugs Market Forecast (2017-2022)
    12.1 Global Urological Cancer Therapeutics Drugs Capacity, Production, Revenue Forecast (2017-2022)
        12.1.1 Global Urological Cancer Therapeutics Drugs Capacity, Production and Growth Rate Forecast (2017-2022)
        12.1.2 Global Urological Cancer Therapeutics Drugs Revenue and Growth Rate Forecast (2017-2022)
        12.1.3 Global Urological Cancer Therapeutics Drugs Price and Trend Forecast (2017-2022)
    12.2 Global Urological Cancer Therapeutics Drugs Production, Consumption , Import and Export Forecast by Region (2017-2022)
        12.2.1 North America Urological Cancer Therapeutics Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.2 Europe Urological Cancer Therapeutics Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.3 China Urological Cancer Therapeutics Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.4 Japan Urological Cancer Therapeutics Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.5 Southeast Asia Urological Cancer Therapeutics Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
        12.2.6 India Urological Cancer Therapeutics Drugs Production, Revenue, Consumption, Export and Import Forecast (2017-2022)
    12.3 Global Urological Cancer Therapeutics Drugs Production, Revenue and Price Forecast by Type (2017-2022)
    12.4 Global Urological Cancer Therapeutics Drugs Consumption Forecast by Application (2017-2022)

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology/Research Approach
        14.1.1 Research Programs/Design
        14.1.2 Market Size Estimation
        14.1.3 Market Breakdown and Data Triangulation
    14.2 Data Source
        14.2.1 Secondary Sources
        14.2.2 Primary Sources
    14.3 Disclaimer